RUXOLITINIB
ruxolitinib 10 mg tablet, 56
RUXOLITINIB (13235N)
13235N
Manner of administration:Oral
Restriction (Streamlined authority code: 13906)
Indication: Moderate to severe chronic graft versus host disease (cGVHD)
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 13867)
Indication: Moderate to severe chronic graft versus host disease (cGVHD)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $4,675.43 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Jakavi | |||||